Pharmaceutical

BeiGene to acquire DualityBio’s ADC therapy for solid tumours

BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.

Jul 11, 2023 - 20:00
BeiGene to acquire DualityBio’s ADC therapy for solid tumours
BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.
Read the original article

Tags:

Previous Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

Next Article

Elsie and GSK link to accelerate oligonucleotide discovery platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Next abortion battles may be among states with clashing laws

Next abortion battles may be among states with clashing...

Apr 11, 2023

Can routinely collected primary care data drive life sciences investment in the UK?

Can routinely collected primary care data drive life sc...

Jun 30, 2024

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

Top 20 biopharma kick off 9.6% market cap surge in Q1 2...

Apr 27, 2024